Anti-Thymocyte Globulin (Equine)
- TRADE NAME: Atgam (Pfizer)
- INDICATIONS: Management of allograft rejection in renal transplant patients, prophylaxis of moderate to severe aplastic anemia in patients who are unsuitable for bone marrow transplantation
- CLASS: Immunosuppressant
- HALF-LIFE: 3–9 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
PREGNANCY CATEGORY: C
Contraindicated in patients who have had a severe systemic reaction during prior administration of any equine gamma globulin preparation.
Please login to see the rest of this drug profile
SKIN.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric